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Abstract Cardiovascular disease is a major cause of morbid-
ity and mortality in patients with type 2 diabetes mellitus, with
a two- to fourfold increase in cardiovascular disease risk com-
pared with non-diabetic individuals. Abnormalities in lipid
metabolism that are observed in the context of type 2 diabetes
are among the major factors contributing to an increased car-
diovascular risk. Diabetic dyslipidaemia includes not only
quantitative lipoprotein abnormalities, but also qualitative
and kinetic abnormalities that, together, result in a shift to-
wards a more atherogenic lipid profile. The primary quantita-
tive lipoprotein abnormalities are increased triacylglycerol
(triglyceride) levels and decreased HDL-cholesterol levels.
Qualitative lipoprotein abnormalities include an increase in
large, very low-density lipoprotein subfraction 1 (VLDL1)
and small, dense LDLs, as well as increased triacylglycerol
content of LDL and HDL, glycation of apolipoproteins and
increased susceptibility of LDL to oxidation. The main kinetic
abnormalities are increased VLDL1 production, decreased
VLDL catabolism and increased HDL catabolism. In addition,
even though LDL-cholesterol levels are typically normal in
patients with type 2 diabetes, LDL particles show reduced
turnover, which is potentially atherogenic. Although the path-
ophysiology of diabetic dyslipidaemia is not fully understood,
the insulin resistance and relative insulin deficiency ob-
served in patients with type 2 diabetes are likely to
contribute to these lipid changes, as insulin plays an
important role in regulating lipid metabolism. In addi-
tion, some adipocytokines, such as adiponectin or
retinol-binding protein 4, may also contribute to the
development of dyslipidaemia in patients with type 2
diabetes.
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The risk of cardiovascular disease and cardiovascular mortal-
ity is significantly increased in patients with type 2 diabetes
mellitus relative to healthy individuals [1, 2]. A major contrib-
utor to the increased cardiovascular risk associated with type 2
diabetes is dyslipidaemia, which encompasses abnormalities
in all lipoproteins [3–5]. Lipid abnormalities observed in type
2 diabetes are not only quantitative, but also qualitative and
kinetic in nature [6–8]. A number of factors may contribute to
the changes in lipid metabolism in patients with type 2
diabetes, including insulin resistance and/or relative
insulin deficiency, adipocytokines (e.g. adiponectin), and
hyperglycaemia [6–8]. The aim of this review is to briefly
describe normal lipoprotein metabolism, including the role
of insulin, to describe the pathophysiology of the lipid abnor-
malities observed in individuals with type 2 diabetes, and to
discuss how these lipid abnormalities relate to the develop-
ment of cardiovascular disease.
Overview of normal lipoprotein metabolism
Lipids are transported within body fluids in the form of lipo-
protein particles, which are classified according to their
density, ranging from chylomicrons to VLDL, intermediate-
density lipoprotein (IDL), LDL and HDL (Fig. 1).
Postprandial lipidaemia and chylomicrons
Dietary lipids are absorbed by the enterocytes via pas-
sive diffusion or specific transporters (e.g. CD36 for
NEFA and Niemann-Pick C1-like 1 protein [NPC1L1]
for cholesterol). Within the enterocytes, triacylglycerols
(triglycerides), cholesteryl esters and other lipids (phos-
pholipids and small amounts of unesterified cholesterol)
are associated with apolipoprotein (Apo)B-48 (as well
as ApoA-IV and ApoA-I) to form chylomicrons in a
process involving microsomal triacylglycerol transfer
protein (MTP) and fatty acid transport proteins.
Chylomicrons are then exported into lymph and subse-
quently into the blood. ApoB-48 synthesis by the gut
occurs continuously; however, lipidation to form chylo-
microns is dependent on the availability of lipids and
occurs mainly after meals.
Lipoprotein lipase (LPL), which is attached to the
luminal surface of endothelial cells and present mostly
in muscles, the heart and the adipose tissue, plays a
major role in chylomicron clearance by hydrolysing tri-













































Fig. 1 An overview of human lipoprotein metabolism and the effects of
insulin on lipoprotein metabolism. (1) Insulin inhibits hormone-sensitive
lipase. (2) Insulin inhibits hepatic VLDL production. (3) Insulin activates
LPL. (4) Insulin increases LRP expression on the plasma membrane. (5)
Insulin increases LDL receptor (LDL-R) expression. CE, cholesterol ester;
CETP, cholesteryl ester transfer protein; HDLn, nascent HDL HL, hepatic
lipase; HSL, hormone-sensitive lipase; LPL, lipoprotein lipase; SR-B1,
scavenger receptor B1; TAG, triacylglycerol
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The chylomicron remnants produced by the lipolysis of
chylomicrons are taken up by the liver via the LDL
receptor (Fig. 1) in conjunction with the LDL
receptor-related protein (LRP), both of which bind
ApoE.
VLDLs and IDLs
Lipids are exported from the liver into the blood as VLDLs.
The first step of VLDL assembly takes place in the rough
endoplasmic ret iculum (ER) where ApoB-100 is
cotranslationally and post-translationally lipidated by MTP,
forming pre-VLDL [9, 10]. In the absence of adequate core
lipids and/or MTP, partially translocated ApoB is exposed to
the cytosol and subjected to degradation via the ubiquitin–
proteasome system. During the second step, pre-VLDL is fur-
ther lipidated late in the ER compartment to form VLDL2,
exiting the ER compartment via Sar1 (a GTPase)/coat protein
II (COPII) vesicles that fuse to the cis side of the Golgi appa-
ratus. In the Golgi apparatus, VLDL2 can be converted into
larger VLDL1 by the addition of lipids (Fig. 2). At this stage,
VLDL particles may also be degraded via post-ER
presecretory proteolysis (PERPP) [11]. The formation of
VLDL1 depends on factors such as ADP ribosylation factor
1 (ARF-1), phospholipase D1 and extracellular signal-
regulated kinase 2 (ERK2), which are involved in membrane
trafficking between the ER and the Golgi apparatus or in the
formation of cytosolic lipid droplets [10].
As with chylomicrons, triacylglycerols from VLDLs are
hydrolysed by LPL in plasma, producing NEFA to be used
as fuel in the heart and skeletal muscle or for storage within
adipocytes (as triacylglycerols). The progressive triacylglyc-
erol depletion of VLDLs induces the transfer of a portion of
the lipoprotein surface layer (including phospholipids, ApoC
and ApoE) to HDLs and leads to the formation of IDLs [8].
Approximately 90% of IDLs are converted into LDL through
further lipolysis involving hepatic lipase, which has both tri-
acylglycerol lipase and phospholipase activities, whereas the
rest is cleared by the liver (via LRP or LDL receptors).
LDLs
LDL, the major transporter of cholesterol within the blood,
comprises a core of esterified cholesterol molecules enclosed
in a shell of phospholipids and unesterified cholesterol, to-
gether with a single molecule of ApoB-100. LDL is taken up
into cells via receptor-mediated endocytosis, which involves,
first, the binding of LDL–ApoB-100 to the LDL receptor on
the plasma membrane of hepatic and other tissues, then the
internalisation of the LDL-receptor complex via endocytosis,
followed by fusion with lysozymes, which contain a number
of catabolic enzymes. Proprotein convertase subtilisin/kexin
type 9 (PCSK9) plays a key role in regulating LDL-receptor
activity by binding the LDL-receptor/LDL complex and
directing the receptor away from recycling back to the surface
and into the lysosomal catabolic pathway.




















Fig. 2 An overview of VLDL
assembly and secretion. Step 1: In
the rough ER, ApoB is lipidated
by MTP, leading to the formation
of pre-VLDL, then VLDL2 by
further lipidation. VLDL2 exits
the ER compartment via
Sar1/COPII vesicles, which are
directed to the Golgi apparatus.
ARF-1 is involved in VLDL2
trafficking between the ER and
the Golgi apparatus. Step 2: In the
Golgi apparatus, VLDL2 is
converted into larger VLDL1 by
the addition of lipids. This step is
promoted by phospholipase D1
and extracellular signal-regulated
kinase 2 (ERK2). At this stage
degradation by PERPP may
occur. COPII, coat protein II;
FA, fatty acid; MTP, microsomal
triglyceride transfer protein; TAG,
triacylglycerol
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HDLs
The atheroprotective effect of HDLs related to their role
in reverse cholesterol transport is well known, but these
lipoprotein particles also have anti-inflammatory, anti-
oxidative, anti-thrombotic and anti-apoptotic properties.
HDLs are synthesised by both the liver and the intes-
tine. Newly secreted or nascent HDLs contain only apo-
lipoproteins (mainly ApoA-I) and rapidly recruit non-
esterified cholesterol and phospholipids from peripheral
cells through the binding of ApoA-I to the membrane-
associated ATP-binding cassette protein 1 (ABCA1)
transporter, allowing for the transport of non-esterified
cholesterol and phospholipids from the cytoplasm into
HDL (Fig. 1) [12]. Within the HDL particle, non-
esterified cholesterol is esterified by lecithin–cholesterol
acyltransferase (LCAT). In the circulation, HDLs acquire
more cholesterol from peripheral tissues, including mac-
rophages within artery walls, again through the ABCA1
transporter, as well as the ATP-binding cassette G1
(ABCG1) transporter. During this process, small-size
HDL (usually called HDL3) becomes larger (usually
called HDL2). HDL returns cholesterol to the liver via
both direct and indirect mechanisms. Through scavenger
receptor B1 (SR-B1), HDL-cholesteryl esters are directly
taken up by the liver, where they are hydrolysed. HDL
also exchanges lipids with VLDL and LDL in a process
involving cholesteryl ester transfer protein (CETP),
whereby cholesteryl esters are transferred from HDL to
VLDL and, reciprocally, triacylglycerols are transferred
from VLDL to HDL. In the circulation, HDL also re-
ceives ApoC and ApoE from VLDL. In addition, phos-
pholipid transfer protein (PLTP) promotes the transfer of
phospholipids from VLDL to HDL. During this process,
HDL becomes enriched in triacylglycerols and phospho-
lipids that are both degraded by hepatic lipase, thus
forming smaller HDL particles that can be cleared by
the liver or again participate in reverse cholesterol trans-
port. During the catabolic process, lipid-poor ApoA-I is
formed that can be filtered at the level of the glomeru-
lus and then catabolised by proximal renal tubular epi-
thelial cells after binding to cubilin, a protein localised
to the apical surface of the renal tubular cell [13].
Lipid transfer proteins
CETP and PLTP play key roles in lipoprotein metabo-
lism. CETP facilitates the transport of cholesteryl esters
and triacylglycerols between the lipoproteins, resulting
in: (1) a net loss of cholesterol esters and gain of tri-
acylglycerols by HDL and LDL; and (2) a reciprocal
net gain of cholesterol esters and loss of triacylglycerols
by chylomicrons and VLDL. CETP activity is increased
by triacylglycerol-rich lipoproteins, NEFA and some
phospholipids (phosphatidylcholine) and is inhibited by
ApoC-I [14]. Any changes in CETP activity significant-
ly modify the composition and metabolism of lipopro-
teins. PLTP circulates in the plasma bound to HDL,
mediating the transfer of phospholipids (e.g. from
VLDL remnants) into these particles, and also the ex-
change of phospholipids between lipoproteins.
Adiponectin
Adiponectin is thought to play a direct role in influenc-
ing lipid metabolism. Adiponectin has been shown to be
inversely correlated with fasting and postprandial triac-
ylglycerols [15, 16]. It facilitates ApoA-I-mediated cho-
lesterol efflux from macrophages by upregulating
ABCA1 expression [17]. In addition, adiponectin is pos-
itively correlated with plasma HDL-cholesterol levels,
and some data indicate that adiponectin may directly
reduce HDL catabolism [18].
The role of insulin in lipoprotein metabolism
Insulin is a key hormone in the regulation of lipid me-
tabolism. The main sites of action of insulin on lipopro-
tein metabolism are shown in Fig. 1. In adipose tissue,
insulin has an antilipolytic effect, inhibiting hormone-
sensitive lipase. Thus, it promotes storage of triacylglyc-
erols in adipocytes and reduces secretion of circulating
NEFA from adipose tissue. This inhibition of lipolysis
by insulin is particularly effective during the postpran-
dial period.
Insulin directly inhibits hepatic VLDL production. In
individuals with normal lipid metabolism, insulin has
been shown to induce a 66% decrease in VLDL-
triacylglycerol production and a 53% decrease in
VLDL-ApoB production [19]. Insulin reduces VLDL
production by diminishing circulating levels of NEFA,
which are substrates for VLDL, and by exerting a direct
inhibitory effect on VLDL production in hepatocytes
[20]. There are several findings indicating that the phos-
phatidylinositol 3-kinase (PI3K) pathway is involved in
the inhibitory effect of insulin on VLDL secretion. The
binding of insulin to its receptor induces tyrosine phos-
phorylation of insulin receptor substrates leading to ac-
tivation of PI3K, which, once activated, induces the
transformation of phosphatidylinositol 4,5-bisphosphate
(PIP2) into phosphatidylinositol 3,4,5-trisphosphate
(PIP3), leading to promotion of the activation of Akt,
a serine/threonine kinase implicated as an effector of
metabolic actions of insulin. Indeed, insulin has been
shown to inhibit, via PI3K, the maturation phase of
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VLDL assembly by preventing bulk lipid transfer to
VLDL precursors [21, 22]. This effect could be partly
explained by the inhibition by insulin of phospholipase
D1 and ARF-1, two factors involved in the formation of
VLDL1 [6, 10]. In addition, insulin activation promotes
the PERPP of ApoB via PI3K [23]. It has also been
shown that insulin reduces the synthesis of ApoB by
inhibiting ApoB mRNA translation [24]. Furthermore,
insulin negatively regulates MTP (also known as
MTTP) gene expression [10]. Insulin is a potent activa-
tor of LPL, promoting the catabolism of triacylglycerol-
rich lipoproteins (e.g. chylomicrons, VLDL) [15].
Insulin also inhibits the expression of ApoC-III, an in-
hibitor of LPL [25]. In addition, it induces the translo-
cation of LRP to the plasma membrane, increasing the
uptake and clearance of chylomicron remnants [26].
Insulin also promotes the clearance of LDL by in-
creasing LDL-receptor expression and activity [27].
Some data indicate that insulin may stimulate the activ-
ity of hepatic lipase [28], but hepatic lipase responsive-
ness to insulin is still controversial [29]. A study on
individuals without diabetes reported that insulin
infusion did not exert any significant effects on LCAT
or CETP activity [30].
Lipid abnormalities in type 2 diabetes
Dyslipidaemia in individuals with type 2 diabetes is very com-
mon, with a prevalence of 72–85% [3, 31]. This phenomenon
is associated with a significantly increased risk of coronary
artery disease relative to individuals without diabetes [3].
Lipid abnormalities observed in patients with type 2 diabetes
play a central role in the development of atherosclerosis.
These lipid abnormalities are not only quantitative, but also
qualitative and kinetic in nature [6–8]. Increased triacylglyc-
erols and reduced HDL-cholesterol are the main quantitative
lipid abnormalities of diabetic dyslipidaemia. In addition, pa-
tients with type 2 diabetes show qualitative and kinetic abnor-
malities for all lipoproteins (see Text box) [6–8, 32]. All of
these abnormalities are known to be risk factors for the devel-
opment of atherosclerosis [33]. The main lipid abnormalities
























































Fig. 3 Main lipid abnormalities in type 2 diabetes. Triacylglycerols
(hypertriglyceridaemia, qualitative and kinetic abnormalities): (1)
increased VLDL production (mostly VLDL1), (2) increased chylomicron
production, (3) reduced catabolism of both chylomicrons and VLDLs
(diminished LPL activity), (4) increased production of large VLDL
(VLDL1), preferentially taken up by macrophages; LDL (qualitative
and kinetic abnormalities): (5) reduced LDL turnover (decreased LDL
B/E receptor), (6) increased number of glycated LDLs, small, dense
LDLs (TAG-rich) and oxidised LDLs, which are preferentially taken up
by macrophages; HDL (low HDL-cholesterol, qualitative and kinetic
abnormalities): (7) increased CETP activity (increased transfer of triac-
ylglycerols from TAG-rich lipoproteins to LDLs and HDLs), (8) in-
creased TAG content of HDLs, promoting HL activity and HDL catabo-
lism, (9) low plasma adiponectin favouring the increase in HDL catabo-
lism. CE, cholesterol esters; CETP, cholesteryl ester transfer protein;
dLDL, small, dense LDL; HDLn, nascent HDL; HL, hepatic lipase;
HSL, hormone-sensitive lipase; LPL, lipoprotein lipase; sLDL-R, LDL
receptor; SR-B1, scavenger receptor B1; TAG, triacylglycerol
890 Diabetologia (2015) 58:886–899
It is important to note that many of the lipid abnormalities
observed in patients with type 2 diabetes exist before the onset
of diabetes as part of the insulin-resistant metabolic syndrome
which is characterised by the accumulation of triacylglycerol-
rich lipoproteins and small, dense LDL particles with reduced
HDL-cholesterol in plasma. These lipid abnormalities are
known to promote cardiovascular disease in individuals with
the metabolic syndrome [34]. This emphasises the important
role of insulin resistance in the pathophysiology of diabetic
dyslipidaemia, which is also highlighted by the presence of
lipid abnormalities typical of diabetic dyslipidaemia in non-
diabetic insulin-resistant first-degree relatives of patients with
type 2 diabetes [35, 36].
Cholesterol absorption and synthesis
Patients with type 2 diabetes have a reduced plasma level of
campesterol, a marker of cholesterol absorption, and increased
plasma levels of lathosterol, a marker of cholesterol synthesis
[37]. Using peroral administration of isotopes, reduced cho-
lesterol absorption and increased cholesterol synthesis have
been demonstrated in patients with type 2 diabetes [38]. The
mechanisms responsible for these changes in cholesterol ho-
meostasis are not yet clarified. In a study performed in 263
patients with type 2 diabetes, liver fat content was indepen-
dently associated with plasma lathosterol [39]. It has been
suggested that this could be due to increased expression of
SREBP2, encoding sterol regulatory element-binding protein,
a factor regulating cholesterol uptake and synthesis, observed
under conditions of increased liver fat content [40].
Postprandial hyperlipidaemia and chylomicrons
In individuals with type 2 diabetes and insulin resistance, an
increase in chylomicron production is observed, contributing
to the postprandial hyperlipidaemia observed in this popula-
tion [41]. Indeed, patients with type 2 diabetes have an in-
creased rate of intestinal ApoB-48 secretion [42] and aug-
mented expression of MTP (responsible for the addition of
triacylglycerols to ApoB-48) within the intestine [43].
Insulin resistance is likely to be involved in the increased
chylomicron production, since the normal acute suppression
of postprandial chylomicron secretion, by insulin, is absent in
patients with type 2 diabetes [44]. In addition, increased
plasma NEFA concentrations (as a result of reduced inhi-
bition of hormone-sensitive lipase in type 2 diabetes [45])
may further drive ApoB-48 secretion [46]. The clearance
of chylomicrons is also impaired in type 2 diabetes [47].
Several mechanisms are responsible for this delayed chy-
lomicron catabolism. The activity of LPL, the enzyme
responsible for chylomicron hydrolysis, is significantly
reduced in patients with type 2 diabetes [15, 48]. Insulin
resistance is also associated with increased plasma levels
of ApoC-III, an inhibitor of LPL [49]. Furthermore, the
activation of LRP (one of the hepatic receptors responsible for
chylomicron remnant uptake) by insulin is abolished in
insulin-resistant mice [26]. The net result of all these
changes is a significantly larger pool of chylomicrons
(hypertriglyceridaemia) (Fig. 3). Moreover, patients with
type 2 diabetes show increased levels of atherogenic remnant
particles, including chylomicron remnants and VLDL rem-
nants [50].
Key changes in lipoprotein metabolism in type 2 diabetes
Lipoprotein Quantitative changes Qualitative changes Kinetic/metabolic changes
Chylomicron • Increased plasma
concentration




VLDL • Increased plasma
concentration
• Greater proportion of larger particles
(VLDL1)
• Increased palmitic acid-containing species




LDL • No change or slightly
increased plasma
concentration
• Greater proportion of small, dense particles
(triacylglycerol enrichment)
• Increased LDL oxidation
• Increased palmitic acid-containing species
and diacylglycerol, reduced sphingomyelin
• Glycation
• Decreased catabolism
HDL • Decreased plasma
concentration
• Triacylglycerol enrichment
• Reduced phospholipids, ApoE and ApoM
• Glycation
• Increased catabolism
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Postprandial hyperlipidaemia is likely to promote athero-
sclerosis and the occurrence of cardiovascular events in pa-
tients with type 2 diabetes. The increase in postprandial triac-
ylglycerols has been shown to be correlated with the increase
in TNFα, IL-6 and vascular cell adhesion molecule 1
(VCAM-1) values, in patients with type 2 diabetes, indicating
a deleterious proinflammatory effect of postprandial hyperlip-
idaemia [51]. Furthermore, the magnitude of postprandial
hypertriglyceridaemia is strongly correlatedwith the reduction
in flow mediated dilatation, in patients with type 2 diabetes,
indicating a role for postprandial hyperlipidaemia in endothe-
lial dysfunction [52].
VLDLs and IDLs
Increased plasma triacylglycerol levels in patients with type 2
diabetes are largely due to an increased number of VLDLs,
particularly large VLDL1 particles [6]. Both increased produc-
tion and delayed catabolism of VLDL are responsible for the
increased VLDL pool. In vivo kinetic studies in patients with
type 2 diabetes have shown an augmented production of both
VLDL-ApoB and VLDL-triacylglycerols [53–55]. More pre-
cisely, it has been demonstrated that type 2 diabetes is associ-
ated with increased production of large VLDL1 particles [56,
57]. Similar increases in VLDL production have been ob-
served in obese, non-diabetic, insulin-resistant individuals,
suggesting a critical role of insulin resistance in the patho-
physiology of VLDL overproduction in type 2 diabetes [58,
59]. It has been shown that the VLDL1 production rate is
correlated with insulin resistance and liver fat in patients with
type 2 diabetes [57, 60].
Insulin resistance is associated with reduced inhibition of
hormone-sensitive lipase in adipose tissue by insulin, leading
to increased lipolysis and, thereby, augmented NEFA portal
flux to the liver. This has been shown to stimulate synthesis of
triacylglycerols in hepatocytes [10]. Furthermore, the normal
suppressant effect of insulin on postprandial VLDL (more
specifically, VLDL1) production is blunted by hepatic insulin
resistance [45, 56, 61]. Several mechanisms seem to be in-
volved in the overproduction of hepatic VLDL relative to
the reduced inhibitory effect of insulin (Fig. 4). First, data
from animal studies have provided evidence that insulin resis-
tance is associated with a reduction in ApoB degradation in
hepatocytes, leading to an increase in the ApoB pool available
for VLDL assembly [62, 63]. Reduced PI3K activity in animal
models, secondary to insulin resistance, has been reported to
increase the expression of protein-tyrosine phosphatase 1B
(PTP-1B), leading to suppression of ER60, a protease associ-
ated with the ER, which promotes ApoB degradation via a
non-proteasomal pathway [62, 64]. In addition, an increased
NEFA level in hepatocytes reduces the post-translational deg-
radation of ApoB. Second, MTP expression is increased in
insulin-resistant states and type 2 diabetes [65]. In insulin
resistance, the reduced activation of PI3K leads to increased
forkhead box protein O1 (FOXO1) activation, which is nor-
mally inhibited by activated PI3K. This increased activation
of FOXO1 is responsible for augmented transcription of the
MTP gene [66]. Third, it has been suggested that insulin re-
sistance could be responsible for the increased activity of two
factors involved in the formation of VLDL1: phospholipase
D1 and ARF-1 [21]. It has also been suggested that decreased
PIP3, secondary to reduced PI3K activation, may also be in-
volved, since PIP3, a highly negatively charged phospholipid,
reduces lipid transfer to VLDL precursor and, thus, the forma-
tion of VLDL1 [22]. It is possible that the increased formation
of VLDL1 automatically reduces the amount of VLDL pre-
cursors available for PERPP and, thus, decreases the rate of
ApoB degradation [22].
In addition, de novo lipogenesis is increased in individuals
with insulin resistance [67]. This increased de novo lipogene-
sis is secondary to augmented expression of both carbohydrate
responsiveness element-binding protein (ChREBP) and sterol
regulatory element-binding protein (SREBP)-1c in insulin re-
sistance and type 2 diabetes [10]. It is suspected that, in pa-
tients with type 2 diabetes, hyperglycaemia directly activates
ChREBP [68]. The increase in SREBP-1c expression could be
related to the augmented ER stress observed in insulin resis-
tance and type 2 diabetes [69]. Based on animal studies, it has
been proposed that hyperinsulinaemia observed in insulin re-
sistance and type 2 diabetesmight be responsible for increased
SREBP-1c expression because insulin stimulates SREBP-1c
transcription. However, this is not supported by data in
humans, since hyperinsulinaemia in patients with insulinoma
is not associated with increased VLDL production [70].
Furthermore, insulin treatment in patients with type 2 diabetes
induces a reduction in liver fat rather than an increase [71].
Moreover, reduced plasma adiponectin levels observed in type
2 diabetes may also promote VLDL production by increasing
plasma NEFA levels, as a consequence of reduced muscle
NEFA oxidation, and by inducing a decrease in AMP-kinase
activation in the liver, which promotes de novo lipogenesis
[10].
As assessed by kinetic studies using radioisotopes [54] and
stable isotopes [53], catabolism of VLDLs is reduced in pa-
tients with type 2 diabetes, which also promotes
hypertriglyceridaemia. This defect in VLDL catabolismmainly
reflects the reduced activity of LPL in type 2 diabetes, particu-
larly in adipose tissue [48]. Since insulin is an activator of LPL,
it has been suggested that the diminution of LPL activity may
be due to a relative insulin deficiency and/or insulin resistance.
In addition, increased plasma levels of ApoC-III (an inhibitor of
LPL) could also contribute to the decreased catabolism of
VLDL in patients with type 2 diabetes, since increased plasma
levels of ApoC-III were associated with impaired VLDL clear-
ance in obese insulin-resistant men [72]. Moreover, postpran-
dially, chylomicrons and VLDL compete for LPL, which
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exacerbates postprandial hypertriglyceridaemia. Most of the
time, hypertriglyceridaemia observed in patients with
type 2 diabetes is mild to moderate but the severity of
hypertriglyceridaemia is also influenced, in each patient,
by the genetic susceptibility [73]. In some sporadic cases of
high genetic susceptibility, severe hypertriglyceridaemia may
develop, with attendant risk of pancreatitis, particularly in
hyperglycaemia [73].
The type of VLDL particles produced in type 2 diabetes is
also altered, with a shift towards a greater proportion of those
of a larger particle size (VLDL1) [32, 74]. Relative to smaller
VLDL particles, these are enriched with cholesterol esters and
phospholipids. Larger triacylglycerol-enriched VLDL parti-
cles are potentially more atherogenic, as indicated by their
significant association with endothelial dysfunction [52],
and their preferential uptake by macrophages, leading to the
formation of foam cells in vessel walls [75]. It has recently
been demonstrated that VLDL from patients with type 2 dia-
betes has increased diacylglycerol content and reduced
sphingomyelin, as well as increased palmitic acid-containing
species [76]. Since palmitate is the major fatty acid synthe-
sised during de novo lipogenesis, the increased palmitic acid
content in VLDL-triacylglycerols might be a consequence of
increased de novo lipogenesis, as suggested by a recent study
that reported increased levels of circulating triacylglycerol-
containing palmitic acid in insulin-resistant obese individuals
with non-alcoholic fatty liver disease [77]. In addition, in-
creased palmitic acid in VLDL-triacylglycerols has been
shown to promote secretion of proinflammatory mediators
by human smooth muscle cells [76]. Glycation of apolipopro-
teins in VLDL (ApoB, ApoCs, ApoE) may occur in diabetes.
This may reduce VLDL binding to the ApoB/E receptor and
hence impair its catabolism [78]. Furthermore, it has been
suggested that glycation of ApoC-II, a cofactor of LPL, could
contribute to lesser LPL activation [79].
LDLs
In patients with type 2 diabetes, the mean LDL-cholesterol
level is comparable or slightly elevated relative to that in in-
dividuals without diabetes [6, 8, 32]. However, the catabolism
of LDL is substantially reduced [53, 80], inducing a longer
duration of LDL in plasma that may promote lipid deposition
within artery walls. In patients with type 2 diabetes, the num-
ber of LDL B/E cell-surface receptors is significantly reduced,
which may be due to reduced insulin-mediated expression and
could be responsible for observed impairments in LDL catab-
olism [81]. It has also been suggested that reduced LDL ca-
tabolism could be partly attributed to a decreased affinity of
LDL for its receptor following ApoB glycation [82].
Proteasome ApoB degradation
Secretion









































Fig. 4 Pathophysiology of increased hepatic VLDL production in type 2
diabetes. 1. Insulin resistance is responsible for: (a) a reduction in ApoB
degradation, leading to an increased ApoB level in hepatocytes (including
ApoB degradation by PERPP); (b) increased MTP expression; and
(c) increased activity of two factors involved in the formation of VLDL1,
phospholipase D1 and ARF-1. Moreover, peripheral insulin resistance is
responsible for increased levels of NEFA, which activate VLDL produc-
tion (see a′′). 2. Increased de novo lipogenesis secondary to: (a′) increased
activation of SREBP-1c (by ER stress); and (b′) increased activation
ChREBP (by hyperglycaemia). 3. Reduced plasma adiponectin level re-
sponsible for: (a′′) increased plasma NEFA levels as a consequence of
reduced muscle NEFA oxidation; and (b′′) a reduction in AMP-kinase
activation in the liver, which promotes de novo lipogenesis. COPII, coat
protein II; ERK2, extracellular signal-regulated kinase 2; FA, fatty acid;
TAG, triacylglycerol;
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As a consequence of hyperglycaemia, increased glycation
of LDL is observed in individuals with type 2 diabetes [83].
Glycated LDL has reduced affinity for LDL B/E receptors
[84] and is preferentially taken up by macrophages, leading
to the formation of foam cells [85]. Another lipoprotein mod-
ification observed in type 2 diabetes that has marked athero-
genic potential is increased LDL oxidation. Patients with type
2 diabetes show increased oxidisability of LDLs and have an
augmented number of oxidised LDL particles in their plasma
[8]. Oxidised LDLs demonstrate a decreased affinity for the
LDL receptor, and are preferentially taken into macrophages
via specific oxidised LDL receptors prior to foam cell devel-
opment [86]. In addition, they have chemoattractant effects on
monocytes by increasing the formation of adhesion mole-
cules, such as intercellular adhesion molecule 1 (ICAM-1),
by endothelial cells, and by stimulating the formation of cy-
tokines, such as TNFα or IL-1, by macrophages, which am-
plifies the inflammatory atherosclerotic process [86].
Small, dense, triacylglycerol-rich LDL particles (known as
subclass B particles) are more prevalent in type 2 diabetes
[87]. This is mainly related to hypertriglyceridaemia, and
VLDL1 triacylglycerol is the major predictor of LDL size in
patients with type 2 diabetes and in non-diabetic individuals
[6]. The characteristic hypertriglyceridaemia observed in pa-
tients with type 2 diabetes stimulates CETP, leading to the
preferential formation of triacylglycerol-rich small, dense
LDL particles over larger ones [74]. The presence of small,
dense LDL particles has been reported to be associated with
increased cardiovascular risk and progression of atherosclero-
sis [88]. Small, dense LDL particles are more atherogenic.
They are more likely to undergo glycation and oxidation than
larger LDL particles, which promotes the generation of foam
cells [8, 89]. In addition, they show increased affinity for
intimal proteoglycans, which may favour the penetration of
LDLs into the arterial wall [90]. Individuals with small, dense
LDL particles have an impaired response to the endothelium-
dependent vasodilator acetylcholine [91]. Furthermore, as
with VLDL, LDL from patients with type 2 diabetes shows
significant changes in both lipid class (increased diacylglyc-
erol and reduced sphingomyelin) and lipid species (increased
palmitic acid-containing species), and the level of palmitic
acid in LDL is correlated with insulin resistance [76].
HDLs
Plasma levels of HDL-cholesterol and ApoA-I are reduced in
patients with type 2 diabetes [6–8]. In particular, the proportion
of circulating smaller HDL particles (HDL3) is increased,
while there are far fewer large HDL particles (HDL2); there-
fore, the overall number of HDL particles is reduced [74].
Reduced levels of HDL2 in patients with type 2 diabetes have
been reported to be associated with both hypertriglyceridaemia
and obesity [92]. Kinetic studies using radioisotopes [93] and
stable isotopes [94] have demonstrated that the decrease in
HDL-cholesterol in patients with type 2 diabetes is due to
increased catabolism of HDLs. The activity of hepatic lipase,
the enzyme controlling HDL catabolism, is augmented
in insulin-resistant states, which is likely to be respon-
sible for the observed increase in HDL catabolism [95].
Hypertriglyceridaemia is a major contributing factor to the
accelerated HDL catabolism observed in type 2 diabetes. It
has recently been demonstrated that both increased VLDL1
production and reduced VLDL1 catabolism are independent
factors associated with increased HDL catabolism in insulin-
resistant states [96]. It is suggested that the increased pool of
triacylglycerol-rich lipoproteins (mainly VLDL1), observed in
type 2 diabetes, promotes CETP-mediated triacylglycerol en-
richment of HDL particles and, as a consequence, enhances
HDL catabolism, since HDL-rich particles are very good sub-
strates for hepatic lipase. The reduction in plasma adiponectin
levels observed in individuals with insulin resistance and type
2 diabetes may be another mechanism involved in the diminu-
tion of HDL-cholesterol levels. Indeed, a significant negative
correlation has been reported between the rate of HDL-ApoA-I
catabolism and plasma levels of adiponectin, independently of
abdominal obesity, insulin sensitivity, age, sex and plasma
lipids, suggesting a direct effect of adiponectin on HDL me-
tabolism [18]; however, its precise role has yet to be
determined.
Several qualitative abnormalities in HDLs have been de-
scribed in patients with type 2 diabetes. They are enriched in
triacylglycerols, and this enrichment is responsible for in-
creased HDL catabolism, as previously discussed.
Furthermore, HDLs are glycated in type 2 diabetes, although
the exact consequences of this glycation remain unknown.
The reduction in phospholipids in large HDL particles in pa-
tients with type 2 diabetes is associated with increased arterial
stiffness [97]. Patients with type 2 diabetes also have reduced
ApoE content in large HDL particles, which may have an
atherogenic effect, since large, ApoE-rich HDL usually pre-
vents LDL binding to proteoglycans in the vessel wall [97].
ApoM, which is mainly associated with HDL, is reduced in
patients with type 2 diabetes due to diabetes-associated obe-
sity [97, 98]. ApoM promotes the formation of pre–β-HDL
from α-HDL, and lower levels of ApoM may explain why
pre-β-HDL formation is not increased in type 2 diabetes, de-
spite increased PLTP activity. ApoMmediates the enrichment
in sphingosine-1-phosphate in HDL, which promotes arterial
vasodilation by stimulating endothelial nitric oxide formation
[99].
In patients with type 2 diabetes, HDL has a reduced capac-
ity to promote ex vivo cholesterol efflux from cells. This may
be due to reduced expression of ABCA1, which is the mem-
brane transporter responsible for the first step of cholesterol
transfer from cell membranes to HDL [100]. Furthermore,
glycation of ABCA1 has been shown to reduce its activity
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[101]. In addition, expression of ABCG1, another transporter
involved in reverse cholesterol transport, is reduced in mono-
cytes from patients with type 2 diabetes, and this is associated
with impaired cholesterol efflux [102].
Reductions in the antioxidative effects of HDLs, promoted
by hyperglycaemia and triacylglycerol enrichment, have been
reported in patients with type 2 diabetes [103]. Furthermore,
the ability of HDL to counteract the inhibition of endothelium-
dependent vasorelaxation induced by oxidised LDL is im-
paired in type 2 diabetes. This reduction in HDL vasorelaxant
effects is inversely correlated with HDL triacylglycerol con-
tent [104]. In line with these data, HDL from patients with
type 2 diabetes has a weaker stimulatory effect on endothelial
nitric oxide synthesis [105].
Lipid transfer proteins
The qualitative lipoprotein abnormalities observed in patients
with type 2 diabetes, such as increased triacylglycerol content
of LDL and HDL particles, indicate increased CETP activity
[106]. The main factor responsible for the increased CETP
activity in type 2 diabetes is the augmented pool of
triacylglycerol-rich lipoproteins (mainly VLDL), which di-
rectly stimulate CETP. However, hyperglycaemia per se could
also activate CETP, since glycation of lipoproteins increases
CETP activity [107]. In addition, a recent study in patients
with diabetes reported that glycation of ApoC-I reduces its
inhibitory effect on CETP [108]. Increased PLTP mass and
PLTP activity have also been reported in patients with type 2
diabetes [109], and this is associated with increased intima–
media thickness [110].
A putative role of some adipocytokines and proteins
in the pathophysiology of diabetic dyslipidaemia?
Adiponectin Adiponectin has a generally anti-atherogenic
profile that may be partly due to its beneficial action on lipid
metabolism [111]. However, adiponectin levels are reduced in
patients with type 2 diabetes, and so its cardioprotective ef-
fects are minimised.
In non-diabetic individuals, as in patients with type 2 dia-
betes, plasma adiponectin is negatively correlated with plasma
triacylglycerols and positively correlated with plasma HDL-
cholesterol, and these associations are independent of insulin
resistance [16, 112]. Low adiponectin plasma levels are asso-
ciated with augmented VLDL catabolism [113] and coupled
with reduced LPL activity in adipose tissue [114] indepen-
dently of insulin resistance, suggesting a possible direct action
of adiponectin on lipid metabolism, independent of its effects
on insulin sensitivity. Adiponectin may decrease plasma triac-
ylglycerols by enhancing NEFA oxidation or by stimulating
lipoprotein lipase [111, 115]. In addition, a significant nega-
tive correlation has been reported between HDL-ApoA-I
catabolism and plasma adiponectin, independent of insulin
resistance and plasma lipids, suggesting a direct effect of
adiponectin on HDL metabolism [18]. However, the exact
mechanisms that may explain a direct effect of adiponectin
on VLDL and HDL have not yet been clarified.
Retinol-binding protein 4 Levels of retinol-binding protein 4
(RBP4), an adipokine secreted by adipocytes and the liver, are
elevated in type 2 diabetes. An independent association be-
tween RBP4 and triacylglycerols has been reported [116,
117]. Moreover, a strong, independent, negative association
has been reported between plasma RBP4 and VLDL catabo-
lism in patients with type 2 diabetes, suggesting that RBP4
may b e i n v o l v e d i n t h e p a t h o p h y s i o l o g y o f
hypertriglyceridaemia in type 2 diabetes [117]. Further studies
are needed to clarify the potential role of RBP4 in diabetic
dyslipidaemia.
Conclusions
Abnormalities of lipoprotein metabolism are one of the
major factors contributing to cardiovascular risk in patients
with type 2 diabetes, and diabetic dyslipidaemia includes not
only quantitative but also qualitative and kinetic lipo-
protein abnormalities that are inherently atherogenic. The
primary (characteristic) quantitative abnormalities are
hypertriglyceridaemia, accompanied by prolonged postpran-
dial hyperlipidaemia and increased levels of remnant particles
(related to the increased production of triacylglycerol-rich li-
poproteins and a reduction in the rate of catabolism of
triacylglycerol-rich lipoproteins), and decreased HDL-
cholesterol levels secondary to an increased rate of HDL ca-
tabolism. The most frequent qualitative abnormalities, which
are potentially atherogenic, include an increase in large VLDL
particle size (VLDL1); a greater proportion of small, dense
LDL particles; an augmented susceptibility of LDLs to oxida-
tion; an increase in triacylglycerol content of both LDL and
HDL; and glycation of apolipoproteins. Although levels of
LDL may be normal in patients with type 2 diabetes, LDL
plasma residence time is increased due to a slower turnover
rate, and this may infer the promotion of lipid deposition
within artery walls. Furthermore, the usual cardioprotective
effects of HDL are reduced or abolished in type 2 diabetes.
Some factors, such as insulin resistance and possibly some
adipokines (e.g. adiponectin) and hyperglycaemia, are in-
volved in the pathophysiology of diabetic dyslipidaemia.
However, many questions remain unanswered (such as the
pathophysiology and the consequences of the qualitative lipid
abnormalities, the precise mechanisms and signalling path-
ways involved in the insulin resistance linked lipid abnormal-
ities, the potential role of adipose tissue and adipocytokines in
the pathophysiology of diabetic dyslipidaemia) and additional
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studies are needed to gain further insight into the precise
mechanisms of diabetic dyslipidaemia. Deeper understanding
of lipid disorders in type 2 diabetes should lead to better treat-
ment of diabetic dyslipidaemia.
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